Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Advances in Breast Cancer Treatment and the St Gallen Breast Cancer Conference

Advances in Breast Cancer Treatment and the St Gallen Breast Cancer Conference

With participation from 105 countries and nearly 2000 doctors specializing in breast cancer, the St. Gallen Breast Cancer Conference held its 17th meeting this year.

In 1987, the St. Gallen Oncology Conference was established as a foundation in St. Gallen, Switzerland, to provide education and build consensus in breast cancer. Since then, the conference has been held every two years to update knowledge and establish a shared international approach to early-stage treatment. This year’s meeting took place in Vienna for the first time.

A New Drug for Stage 4 Breast Cancer

The opening session was dominated by news of FDA approval for the CDK 4/6 inhibitor that doubles disease-free time in metastatic breast cancer: Ribociclib.

Our cells pass through various stages during division. This sequence of events preparing a cell to divide into two daughter cells is called the cell cycle . First, in 1980, American scientist Dr. Leland H. Hartwell and colleagues discovered proteins controlling cell division called cyclins . This discovery earned Dr. Hartwell the Nobel Prize in 2001. Once the effects of cyclins in cancer cells were identified, drug development against these proteins began during the same period.

stage 4 metastatic hormone-positive breast cancer new treatment ribociclib kisquali palbocicl

Proteins called CDK 4/6, part of the mechanisms controlling proliferation, may be overactive in hormone receptor-positive breast cancer and cause excessive cancer-cell division. The eagerly awaited results for ribociclib, which inhibits these proteins, were reported at ESMO 2016. In previously untreated hormone receptor-positive, HER2 receptor-negative disseminated breast cancer, ribociclib doubled the time to progression. Its combination with the hormone-suppressing drug letrozole was approved by the American drug agency, the FDA . Two important questions about these agents arose during discussions on the meeting’s first day.

First: Should This Be First-Line Treatment in Patients with Hormone-Sensitive Disseminated Disease?

Patients with hormone-sensitive, HER2 receptor-negative disease account for approximately %70 of all breast cancers. In stage 4 disease, our aim is control. Because treatment must be planned long term, some patients can receive this approach at a later line. Fulvestrant, an estrogen receptor suppressor with proven success in earlier studies, offers benefit in patients with bone-only metastasis close to that of combined ribociclib and letrozole. Fulvestrant may therefore be considered first for limited disease involving bone only, while combined ribociclib and letrozole should be prioritized for spread to organs.

Second: Will a Drug So Successful in Disseminated Disease Also Work as Preventive (Adjuvant) Treatment After Surgery?

Unfortunately, we do not yet know. Many studies are ongoing, but completing them will take time because results in patients receiving adjuvant treatment require follow-up periods of five or more. Alongside this preventive approach, studies investigating the effectiveness of preoperative tumor-shrinking (neoadjuvant) treatments also continue.

For our stage 4 patients, minimizing side effects is as important as treatment’s contribution to survival. Because treatment is planned long term, patients should tolerate it easily without impaired quality of life. The most common side effect of CDK 4\6 inhibitors is a decrease in white blood cells (neutrophils), basic components of the immune system.

By suppressing dividing cells, these drugs stop their production. This is manageable: the effect reverses within days after stopping the drug, and only % 3 of patients develop infection-associated (neutropenic) fever, making use easier. Studies have shown these drugs to be safe and easily tolerated regarding other side effects. Although these CDK 4\6 inhibitors clearly work in hormone-sensitive disseminated disease, patients must be carefully selected. Studies of biomarkers are also needed to show who benefits more.

These newly developed agents provide many treatment alternatives that can be used long term for disseminated breast cancer. Your physician will identify the most appropriate option for you.

Sources

1. The Nobel Prize in Physiology or Medicine 2001, Illustrated Lecture

2. Hortobagyi GN, et al. N Engl J Med. 2016;37 5:1738-1748

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Advances in Breast Cancer Treatment and the St Gallen Breast Cancer Conference

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy